Clinical trials: Resolution
Cystic Fibrosis
Aztreonam Lysine for Pseudomonas Infection Eradication Study
This is an open-label, multi-center study in pediatric patients age 3 months to less than 18 years with cystic fibrosis (CF) and newly detected Pseudomonas aeruginosa (PA) pulmonary colonization/infection.
- Trial name
- ALPINE (NCT01375049)
- Testing
- Aztreonam for Inhalation Solution (AZLI)
- Where
- 58 sites in United States, Austria and 7 more
- Volunteers
- 105 people
- Sponsor
- Gilead Sciences
Idiopathic Pulmonary Fibrosis
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
This is an 6 month multi-centre, prospective, randomized, placebo controlled, double blind clinical trial followed by conversion of each arm to active nintedanib for an additional 6 months comparing the effect of nintedanib 150mg…
- Trial name
- NCT01979952
- Testing
- Nintedanib
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 113 people
- Sponsor
- Boehringer Ingelheim
Acne Vulgaris
Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne
The purpose of this study is to determine and compare the safety and efficacy of multiple broad area photodynamic therapy treatments with aminolevulinic acid (ALA-PDT) and vehicle (VEH-PDT) in subjects with moderate to severe…
- Trial name
- NCT00706433
- Testing
- aminolevulinic acid HCL (ALA), Vehicle (VEH)
- Where
- 14 sites in United States
- Volunteers
- 266 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Gonarthrosis, Knee Osteoarthritis
Evaluation of Intra-articular Injection of Autologous Protein Solution ("APS(TM)") for the Treatment of Osteoarthritis (OA)
This prospective single-center study will evaluate the safety and tolerability of a single dose of "APS(TM)" treated patients with OA of the knee who have failed conservative OA therapy.
- Conditions
- Gonarthrosis, Knee Osteoarthritis, Osteoarthritis
- Trial name
- NCT01773226
- Testing
- Autologous Protein Solution "APS(TM)"
- Where
- Netherlands
- Volunteers
- 11 people
- Sponsor
- Zimmer Biomet
Infection; Dialysis Catheter
Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections
Aim: To conduct a randomized, double-blinded, controlled phase II trial to investigate the use of a catheter lock solution consisting of N-acetylcysteine, tigecycline and heparin, in addition to systemic antibiotics, for the…
- Trial name
- NCT01483872
- Testing
- NAC/Tigecycline/Heparin combination lock solution, Standard anticoagulant (Heparin or Citrate)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of California, San Diego
Adolescent Behavior, Interpersonal Relations
Me & You-Tech: A Socio-Ecological Solution to Teen Dating Violence for the Digital Age
The purpose of this study is to develop and evaluate a multi-level (youth, parent, school) Internet-based dating violence prevention program, 'Me \& You-Tech' (MYT) for 6th-grade middle school students.
- Conditions
- Adolescent Behavior, Interpersonal Relations, Domestic Violence, Physical Violence
- Trial name
- MYTech (NCT05225727)
- Testing
- Me & You - Tech
- Where
- United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Chronic Obstructive Pulmonary Disease
Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and ability of several doses of an orally inhaled medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered with an electronic eFlow nebulizer system in…
- Trial name
- NCT02951312
- Testing
- Glycopyrrolate Inhalation Solution 25mg, Glycopyrrolate Inhalation Solution 75mg, Glycopyrrolate Inhalation Solution 200mg
- Volunteers
- 12 people
- Sponsor
- Sunovion Respiratory Development Inc.
Nail Psoriasis
Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis
The purpose of this study is to compare the efficacy and safety of indigo naturalis oil extract and calcipotriol solution in the treatment of psoriatic nails, to show that indigo naturalis oil extract may be a good choice for…
- Trial name
- NCT01445886
- Testing
- Indigo Naturalis Extract in Oil, Calcipotriol Solution
- Where
- Taiwan
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Yin-ku Lin
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
- Trial name
- NCT02674854
- Testing
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Aerie Pharmaceuticals
Female Pattern Hair Loss, Androgenic Alopecia
Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia
The purpose of this study is to characterize the effect of Minoxidil 2% Solution and Botanical Hair Solution Regimen in women with thinning hair and female pattern hair loss/androgenic alopecia (Ludwig I and II).
- Trial name
- NCT02460497
- Testing
- Treatment: Minoxidil 2% / Botanical Hair Solution for Women
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Galderma R&D
Allergic Conjunctivitis
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
- Trial name
- NCT01743027
- Testing
- AL-4943A ophthalmic solution, Olopatadine hydrochloride ophthalmic solution, 0.2%, Olopatadine hydrochloride ophthalmic solution, 0.1%
- Volunteers
- 902 people
- Sponsor
- Alcon Research
Hyperemia Eye
Safety and Tolerability of PRO-185
Phase I Study to evaluate safety and tolerability of PRO-185 (naphazoline/hypromellose) ophthalmic solution through evaluation of vital signs, ocular signs such as intraocular pressure, hyperemia and mydriasis and adverse events.
- Trial name
- PRO-185 (NCT05470868)
- Testing
- Naphazoline / Hypromellose Ophthalmic
- Where
- Mexico
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Allergic Conjunctivitis
Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)
To evaluate the efficacy of olopatadine 0.1% using the OHIO Chamber in patients with seasonal allergic conjunctivitis.
- Trial name
- NCT00818805
- Testing
- Olopatadine 0.1%, Tranilast 0.5%
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Sjogren's Syndrome, Dry Eye
Nasal Spray Study in Sjogren's Dry Eye Disease
This study will investigate how well OC-01 (varenicline) nasal spray can treat the signs and symptoms of dry eye disease in those Sjogren's Syndrome.
- Trial name
- NCT05700422
- Testing
- Varenicline Nasal Spray
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pennsylvania
Allergic Conjunctivitis
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01685242
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Aciex Therapeutics, Inc.
Bioequivalence
Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed Conditions
This is a single center, Phase 1, randomized, open-label, single-dose, 2 treatment, 2-period,2-sequence, crossover study designed to compare the pharmacokinetics (PK) of sapropterin between the Test and Reference products in…
- Trial name
- NCT06987773
- Testing
- RLF-OD032 100 mg/mL oral suspension, Kuvan 100 MG Powder for Oral Solution
- Where
- Canada
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- APR Applied Pharma Research s.a.
Dry Eye Disease
Phase II Study of SHJ002 Sterile Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
The purpose of this study is to measure efficacy and safety with SHJ002 sterile ophthalmic solution compared to vehicle in participants with Dry Eye Disease (DED).
- Trial name
- NCT05486728
- Testing
- SHJ002/Vehicle
- Where
- 4 sites in Australia, Taiwan and 1 more
- Volunteers
- 85 people
- Sponsor
- Dreamhawk Vision Biotech, Inc.
Sialorrhoea
A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
The purpose of this study is to determine whether OC (oxybutynin and clonidine) oral solution is effective in reducing saliva secretion in patients suffering from Parkinson's Disease with excessive salivation.
- Trial name
- NCT01370811
- Testing
- oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Orient Pharma Co., Ltd.
Healthy
A Study in Healthy Men to Test How BI 764198 is Processed in the Body
The main objective of this trial is to investigate the basic pharmacokinetics of BI 764198 and its metabolites, total radioactivity including mass balance, excretion pathways and metabolism following oral administration to…
- Trial name
- NCT05863130
- Testing
- BI 764198 (C-14) (approach 1), BI 764198 (C-14) (approach 2)
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
28-Day double-blinded efficacy and safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.
- Trial name
- (HOPE-1) (NCT03229252)
- Testing
- SPX-101
- Where
- 25 sites in Canada, France and 3 more
- Volunteers
- 91 people
- Sponsor
- Spyryx Biosciences, Inc.